-+ 0.00%
-+ 0.00%
-+ 0.00%

SIGNATERA™ RECEIVES REGULATORY APPROVAL IN JAPAN AS A COMPANION DIAGNOSTIC IN MUSCLE-INVASIVE BLADDER CANCER

路透·09/22/2026 12:00:05

登录查看新闻详情